retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs

The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still undetermined. In particular, the recommended target of hematocrit (Hct)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2010-07, Vol.89 (7), p.691-699
Hauptverfasser:	Crisà, Elena, Venturino, Ermanno, Passera, Roberto, Prina, Marco, Schinco, Piercarla, Borchiellini, Alessandra, Giai, Valentina, Ciocca Vasino, Maria Ausilia, Bazzan, Mario, Vaccarino, Antonella, Boccadoro, Mario, Ferrero, Dario
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adolescent Adult Aged Aged, 80 and over chemotherapy Disease-Free Survival Female Follow-Up Studies Hematocrit Hematology Humans Leukemia, Myeloid, Acute - blood Leukemia, Myeloid, Acute - complications Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Platelet Aggregation Inhibitors Polycythemia vera Polycythemia Vera - blood Polycythemia Vera - complications Polycythemia Vera - drug therapy Polycythemia Vera - mortality Practice Guidelines as Topic Retrospective Studies Survival Rate Thrombosis - blood Thrombosis - complications Thrombosis - drug therapy Thrombosis - mortality Thrombotic events
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still undetermined. In particular, the recommended target of hematocrit (Hct)
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-009-0899-z